Filtered By:
Condition: Thrombosis
Drug: Activase
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 351 results found since Jan 2013.
Evolving Thrombolytics: from Alteplase to Tenecteplase
AbstractAlteplase has been the primary thrombolytic used in the treatment of acute ischemic stroke since thrombolysis was first established as an effective treatment of acute ischemic stroke in 1995. Tenecteplase, a genetically modified tissue plasminogen activator, has gained attention as an attractive alternative to alteplase given its practical workflow advantages and possible superior efficacy in large vessel recanalization. As more data is analyzed both from randomized trials and non-randomized patient registries, there is mounting support that tenecteplase appears to be at least equally, if not more, safe and potenti...
Source: Neurotherapeutics - June 5, 2023 Category: Neurology Source Type: research
Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research
Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke
This randomized clinical trial of individuals with ischemic stroke assesses the safety and efficacy of treatment with a dual plasminogen activator vs usual treatment with intravenous alteplase.
Source: JAMA Neurology - May 22, 2023 Category: Neurology Source Type: research
Identification, characterization, and engineering of glycosylation in thrombolyticsa
Biotechnol Adv. 2023 May 12:108174. doi: 10.1016/j.biotechadv.2023.108174. Online ahead of print.ABSTRACTCardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary embolism, are the most common causes of disability and death worldwide. Blood clot hydrolysis by thrombolytic enzymes and thrombectomy are key clinical interventions. The most widely used thrombolytic enzyme is alteplase, which has been used in clinical practice since 1986. Another clinically used thrombolytic protein is tenecteplase, which has modified epitopes and engineered glycosylation sites, suggesting that carbohydrate modifica...
Source: Biotechnology Advances - May 14, 2023 Category: Biotechnology Authors: Martin Toul Veronika Slonkova Jan Mican Adam Urminsky Maria Tomkova Erik Sedlak David Bednar Jiri Damborsky Lenka Hernychova Zbynek Prokop Source Type: research
Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
ConclusionsStandard-dose alteplase treatment reduced the risk of long-term recurrence of AIS after hospital discharge and the alteplase dose was not associated with the long-term risk of death from AIS.
Source: Neurology and Therapy - May 11, 2023 Category: Neurology Source Type: research
Early recanalization with intravenous thrombolysis before mechanical thrombectomy: considerations to explore with tenecteplase
Time is brain. Hence, timely reperfusion in emergent large vessel occlusion (LVO) stroke is critical for favorable outcomes. Intravenous thrombolysis with alteplase (TPA) before mechanical thrombectomy (MT) for emergent LVO stroke is associated with significantly higher rates of preinterventional reperfusion than MT alone. Recent post hoc analyses of SWIFT-DIRECT and DIRECT-MT have shown that times longer than 30 min since TPA administration are associated with increased reperfusion rates.1 2 The incremental increase of reperfusion rates with longer times since TPA administration underpins TPA’s time dependence to ex...
Source: Journal of NeuroInterventional Surgery - April 13, 2023 Category: Neurosurgery Authors: Hendrix, P., Schirmer, C. M. Tags: Letter Source Type: research
